Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil

Emanuele Cozzani, Elisa Cinotti, Raffaella Felletti, David Pelucco, Alfredo Rebora, Aurora Parodi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Amyopathic dermatomyositis (ADM) causes a severe pulmonary disease in 50% of patients and no validated therapeutic option is available. Mycophenolate mofetil permitted to control interstitial lung disease and pneumomediastinum in a patient with ADM. This drug has recently been used to treat interstitial lung disease in ADM, but its effectiveness has not been previously reported in case of pneumomediastinum. Patients with ADM need an accurate pulmonary surveillance and in case of pulmonary complications mycophenolate mofetil could be a new therapeutic option.

Original languageEnglish
Pages (from-to)687-692
Number of pages6
JournalImmunopharmacology and Immunotoxicology
Volume35
Issue number6
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Mycophenolic Acid
Pulmonary diseases
Mediastinal Emphysema
Lung
Interstitial Lung Diseases
Lung Diseases
Pharmaceutical Preparations
Amyopathic dermatomyositis
Therapeutics

Keywords

  • Autoimmune disease
  • Connective tissue disease
  • Corticosteroids
  • Lung involvement
  • Therapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology

Cite this

Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. / Cozzani, Emanuele; Cinotti, Elisa; Felletti, Raffaella; Pelucco, David; Rebora, Alfredo; Parodi, Aurora.

In: Immunopharmacology and Immunotoxicology, Vol. 35, No. 6, 12.2013, p. 687-692.

Research output: Contribution to journalArticle

Cozzani, Emanuele ; Cinotti, Elisa ; Felletti, Raffaella ; Pelucco, David ; Rebora, Alfredo ; Parodi, Aurora. / Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. In: Immunopharmacology and Immunotoxicology. 2013 ; Vol. 35, No. 6. pp. 687-692.
@article{cec32925fe084337b3494c189e541c9a,
title = "Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil",
abstract = "Amyopathic dermatomyositis (ADM) causes a severe pulmonary disease in 50{\%} of patients and no validated therapeutic option is available. Mycophenolate mofetil permitted to control interstitial lung disease and pneumomediastinum in a patient with ADM. This drug has recently been used to treat interstitial lung disease in ADM, but its effectiveness has not been previously reported in case of pneumomediastinum. Patients with ADM need an accurate pulmonary surveillance and in case of pulmonary complications mycophenolate mofetil could be a new therapeutic option.",
keywords = "Autoimmune disease, Connective tissue disease, Corticosteroids, Lung involvement, Therapy",
author = "Emanuele Cozzani and Elisa Cinotti and Raffaella Felletti and David Pelucco and Alfredo Rebora and Aurora Parodi",
year = "2013",
month = "12",
doi = "10.3109/08923973.2013.833624",
language = "English",
volume = "35",
pages = "687--692",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil

AU - Cozzani, Emanuele

AU - Cinotti, Elisa

AU - Felletti, Raffaella

AU - Pelucco, David

AU - Rebora, Alfredo

AU - Parodi, Aurora

PY - 2013/12

Y1 - 2013/12

N2 - Amyopathic dermatomyositis (ADM) causes a severe pulmonary disease in 50% of patients and no validated therapeutic option is available. Mycophenolate mofetil permitted to control interstitial lung disease and pneumomediastinum in a patient with ADM. This drug has recently been used to treat interstitial lung disease in ADM, but its effectiveness has not been previously reported in case of pneumomediastinum. Patients with ADM need an accurate pulmonary surveillance and in case of pulmonary complications mycophenolate mofetil could be a new therapeutic option.

AB - Amyopathic dermatomyositis (ADM) causes a severe pulmonary disease in 50% of patients and no validated therapeutic option is available. Mycophenolate mofetil permitted to control interstitial lung disease and pneumomediastinum in a patient with ADM. This drug has recently been used to treat interstitial lung disease in ADM, but its effectiveness has not been previously reported in case of pneumomediastinum. Patients with ADM need an accurate pulmonary surveillance and in case of pulmonary complications mycophenolate mofetil could be a new therapeutic option.

KW - Autoimmune disease

KW - Connective tissue disease

KW - Corticosteroids

KW - Lung involvement

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84887949089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887949089&partnerID=8YFLogxK

U2 - 10.3109/08923973.2013.833624

DO - 10.3109/08923973.2013.833624

M3 - Article

VL - 35

SP - 687

EP - 692

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 6

ER -